Independence Blue Cross has agreed to cover Interpace Diagnostics' ThyGeNext and ThyraMir molecular thyroid tests, which help assess if initial indeterminate thyroid nodules biopsies are benign or cancerous. The decision makes the tests available to around 2.5 million patients in Southeastern Pennsylvania and Philadelphia.
Independence Blue Cross now covers Interpace's thyroid tests
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.